57.0707.95% ( -4.930 )
Closed: Oct 30, 16:00:00 (EDT)Current ValuationThe current P/E ratio is -81.34, within the reasonable range, cheaper than 69.73% of the time in the past 3 years, and the industry ranks 54/58, the industry Median -2.38.
-81.34xP/E
$57.07Stock price
$-0.70Earnings per share
-81.34xP/E
Stock price$57.07Earnings per share$-0.70
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 26.90x
- Typical range
- -235.84x–58.00x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
010203040
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
LZAGYUSLonza | -394.89x | -- | $54.37B |
CRLUSCharles River Laboratorie | -71.95x | 238.50% | $17.16B |
TEMUSTempus AI | -50.93x | 1.11% | $12.96B |
RGENUSRepligen | -845.96x | 133.43% | $9.99B |
TXGUS10X Genomics | -121.59x | 108.91% | $9.13B |
BRKRUSBruker | -81.34x | 7.71% | $8.70B |
ADPTUSAdaptive Biotechnologies | -66.58x | 38.37% | $4.25B |
ABCLUSAbcellera Biologics | -24.15x | 36.29% | $3.98B |
ALMRUSAlamar Biosciences | -42.76x | 80.56% | $2.12B |
MRVIUSMaravai LifeSciences | -26.21x | 64.44% | $2.03B |
FTREUSFortrea | -29.47x | 95.84% | $2.02B |
AZTAUSAzenta | -13.92x | 176.92% | $1.71B |
PSNLUSPersonalis | -15.76x | 18.96% | $1.69B |
CYRXUSCryoport | -19.30x | 156.25% | $875.72M |
PACBUSPacific Biosc California | -6.16x | 75.55% | $809.71M |
CTKBUSCytek Biosciences | -9.89x | 33.98% | $796.80M |
DNAUSGinkgo Bioworks | -2.60x | 35.20% | $754.88M |
OABIUSOmniAb | -17.09x | 35.96% | $742.94M |
EVOUSEvotec SE | -2.38x | 385.41% | $543.47M |
TKNOUSAlpha Teknova | -27.08x | 7.81% | $454.13M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
